Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has been given a consensus rating of “Strong Buy” by the eight brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, one has issued a buy recommendation and six have given a strong buy recommendation to the company.
Several analysts recently commented on GLX shares. ATB Cormark Capital Markets lowered Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a report on Thursday, February 5th. Citizens Jmp upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, December 9th.
Read Our Latest Research Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
